Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$70.39 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
327.07 million
Earnings per share
-0.014
Dividend per share
N/A
Year To Date Return
81.48%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Share Market News
What is going on with the Rhythm (ASX:RHY) share price today?
Share Market News
The Rhythm (ASX:RHY) share price surges on cancer testing milestone
Share Market News
Which ASX healthcare shares saw the biggest gains in February?
Share Market News
What's happening with the Rhythm (ASX:RHY) share price today?
Share Market News
Why the Rhythm (ASX:RHY) share price again reached a new all-time record today
Share Market News
Here's why the Rhythm (ASX:RHY) share price hit an all-time high today
Share Market News
Rhythm Biosciences (ASX: RHY) share price soars 1300% in 6 months
Share Gainers
Here's why the Rhythm Bioscience (ASX:RHY) share price is up 15% to a record high
Share Market News
Why the Rhythm Biosciences (ASX:RHY) share price jumped over 600% this year
Share Market News
The Rhythm (ASX:RHY) share price is surging 5% higher today. Here's why.
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price rocketed 28% to a record high
Share Gainers
These small cap ASX shares delivered more than 100% returns in November
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Feb 2026 | $0.22 | $-0.01 | -4.55% | 379,235 | $0.22 | $0.22 | $0.20 |
| 26 Feb 2026 | $0.22 | $-0.01 | -4.44% | 442,428 | $0.23 | $0.23 | $0.22 |
| 25 Feb 2026 | $0.23 | $0.02 | 9.76% | 890,947 | $0.23 | $0.23 | $0.22 |
| 20 Feb 2026 | $0.21 | $-0.01 | -4.65% | 600,326 | $0.21 | $0.21 | $0.20 |
| 19 Feb 2026 | $0.22 | $0.00 | 0.00% | 503,825 | $0.22 | $0.23 | $0.21 |
| 18 Feb 2026 | $0.22 | $0.01 | 4.76% | 1,003,500 | $0.22 | $0.22 | $0.21 |
| 17 Feb 2026 | $0.21 | $0.01 | 4.88% | 1,451,816 | $0.23 | $0.24 | $0.21 |
| 16 Feb 2026 | $0.21 | $-0.01 | -4.76% | 600,062 | $0.21 | $0.22 | $0.21 |
| 13 Feb 2026 | $0.21 | $-0.03 | -12.50% | 1,375,589 | $0.24 | $0.24 | $0.21 |
| 12 Feb 2026 | $0.24 | $-0.01 | -4.08% | 574,887 | $0.25 | $0.25 | $0.23 |
| 11 Feb 2026 | $0.25 | $0.02 | 8.89% | 1,452,574 | $0.26 | $0.27 | $0.25 |
| 10 Feb 2026 | $0.23 | $-0.03 | -11.76% | 2,361,966 | $0.25 | $0.26 | $0.21 |
| 09 Feb 2026 | $0.26 | $0.01 | 4.08% | 2,469,619 | $0.26 | $0.27 | $0.24 |
| 06 Feb 2026 | $0.25 | $0.01 | 4.26% | 3,593,802 | $0.23 | $0.28 | $0.21 |
| 05 Feb 2026 | $0.24 | $0.06 | 34.29% | 4,473,786 | $0.18 | $0.24 | $0.18 |
| 04 Feb 2026 | $0.18 | $-0.02 | -10.53% | 371,205 | $0.19 | $0.19 | $0.18 |
| 03 Feb 2026 | $0.19 | $0.04 | 26.67% | 2,755,061 | $0.17 | $0.20 | $0.17 |
| 02 Feb 2026 | $0.15 | $0.01 | 6.90% | 438,104 | $0.15 | $0.17 | $0.15 |
| 30 Jan 2026 | $0.15 | $-0.03 | -17.65% | 1,546,739 | $0.17 | $0.17 | $0.14 |
| 29 Jan 2026 | $0.17 | $0.02 | 13.33% | 2,553,566 | $0.15 | $0.18 | $0.15 |
| 28 Jan 2026 | $0.15 | $0.01 | 7.14% | 644,130 | $0.15 | $0.16 | $0.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Dec 2025 | David Atkins | Issued | 100,000 | $8,600 |
Issue of options.
|
| 02 Dec 2025 | Gavin Fox-Smith | Issued | 277,777 | $23,888 |
Issue of options.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 1,027,777 | $99,999 |
Issue of securities.
|
| 01 Dec 2025 | Gavin Fox-Smith | Issued | 750,000 | $66,000 |
Issue of options.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $39,600 |
Issue of options.
|
| 01 Dec 2025 | Sue(Susan) MacLeman | Issued | 450,000 | $45,000 |
Issue of securities.
|
| 01 Dec 2025 | David Atkins | Issued | 466,820 | $41,080 |
Issue of options.
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
| 01 Dec 2025 | David Atkins | Transfer | 4,000,000 | $352,000 |
Off-market transfer. assuming off market transfer
|
| 01 Dec 2025 | David Atkins | Issued | 1,093,001 | $108,300 |
Issue of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Atkins | Chief Executive OfficerManaging Director | May 2024 |
Dr Atkins is a healthcare leader with global markets experience across a board range of life sciences and healthcare disciplines, having gained experience in R&D, product development and commercialization across biotech, medical device, IVD and data-driven solutions in all global markets. Over the last 30 years, he has held national, regional and global roles across the Pharmaceutical, medical device and diagnostics sectors.
|
| Mr Gavin Fox-Smith | Non-Executive Director | Dec 2024 |
Mr Smith has 38-year experience in Medical Technology in Australia/NZ and Asia. He has also played lead Governance and Executive roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is an advocate for Gender Equality and Indigenous Engagement. Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Non-Executive Director for Omnigon, Bowel Cancer Australia and SAN Foundation.
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Mr Todd Perkinson | Chief Financial Officer |
-
|
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Catapult Investors Pty Ltd | 22,479,168 | 7.91% |
| HSBC Custody Nominees (Australia) Limited | 17,982,996 | 6.33% |
| Newfound Investments Pty Ltd | 13,905,407 | 4.89% |
| Loumea Investment Pty Ltd | 8,052,520 | 2.83% |
| J P Morgan Nominees Australia Pty Limited | 6,522,164 | 2.30% |
| Rojo Nero Capital Pty Ltd | 4,541,619 | 1.60% |
| Dc & Pc Holdings Pty Ltd | 4,465,567 | 1.57% |
| Ferndale Securities Pty Ltd | 4,300,000 | 1.51% |
| BNP Paribas Nominees Pty Ltd | 4,224,507 | 1.49% |
| Mr Martin Paul Breslin <The Mpb A/C> | 4,000,000 | 1.41% |
| Giokirptyltd | 3,661,470 | 1.29% |
| Mr Martin Paul Breslin | 3,175,000 | 1.12% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 3,000,000 | 1.06% |
| Mr Adrian Darby | 2,512,328 | 0.88% |
| Commonwealth Scientific And Industrial Research Organisation | 2,500,000 | 0.88% |
| Finclear Services Nominees Pty Limited | 2,325,463 | 0.82% |
| E&W Nominee Pty Ltd | 2,207,941 | 0.78% |
| Ms Natalie Louise Patterson | 2,200,000 | 0.77% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 2,150,000 | 0.76% |
| Mr Hsien Michael Soo | 2,134,442 | 0.75% |
